Acelity said today it inked a deal to acquire advanced wound care and dermatology company Crawford Healthcare for an undisclosed amount.
San Antonio, Texas-based Acelity said that the acquisition of Crawford will expand its advanced wound dressing product portfolio and strengthen its position in the advanced wound care market worldwide.
Crawford Healthcare produces the KerraMax Care line of wound dressings and the KerraFoam and KerraCel foam and antimicrobial gelling fiber advanced wound dressings, Acelity said. Acelity touted that the combination of both its and Crawford’s wound care portfolios will create “the world’s most expansive wound care portfolio.”
“The rapid growth of the business has been possible due to our focused investment in innovative products which are clinically proven to improve patient outcomes. Becoming part of the world’s largest wound care company will provide us with the scale to optimize our potential within the US, the largest global market and the ability to further access and grow in other international markets with our best-in-class advanced wound care products,” Crawford Helathcare CEO Richard Anderson said in a press release.
Acelity said it is also acquiring Crawford’s research & development and manufacturing operations in Cheshire, U.K., and that former CEO Anderson will stay on to lead the acquired division as it integrates into Acelity.
“Crawford’s talented team, highly complementary line of advanced wound dressings, and track record of patient-focused innovation make them a terrific partner to accelerate our global growth. This transaction solidifies our ability to offer the most comprehensive line of wound care solutions and will enable us to create and consolidate leading positions in high-growth market segments; expand and strengthen our customer relationships; and enhance our innovation expertise for the benefit of clinicians and patients around the world,” Acelity prez & CEO R. Eckert said in a prepared statement.
In February, a report emerged claiming that Acelity was set to lay off 68 employees at its San Antonio, Texas facilities.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.